scholarly journals Altered Levels of Neurotrophic Factors in Alzheimer's Disease Patients with a Lifetimne History of Depression

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
M.A. Rapp ◽  
V. Haroutunian ◽  
A. Heinz
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Major Depression ◽  
Neurotrophic Factors ◽  
Major Depressive ◽  
Neurotrophin 3 ◽  
Co Morbidity ◽  
History Of ◽  
Underlying Mechanisms ◽  
History Of Depression

Aims:We have recently shown both increases in the number of neuropathological changes in Alzheimer's disease patients with a history of recurrent major depression, and evidence for Alzheimer's disease-related neuropathological changes in patients with geriatric major depression. However, the correlates and possible underlying mechanisms for these neuropathological changes in Alzheimer's disease patients as a function of depression remains to be studied.Method:Levels of several neurotrophic factors, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3) were measured in a sample of Alzheimer's disease patients with and without a lifetime history of major depressive disorder.Results:Alzheimer's disease patients with co-morbid depression showed lower levels BDNF (P < .001) and NGF (P < .001) than Alzheimer's disease patients without co-morbid depression. Results remained stable when controlling for age, gender, level of education, and other medical co-morbidities.Conclusion:In Alzheimer's disease, the presence of depression co-morbidity corresponds to decreases in neurotrophic factors beyond effects of age, education, and medical co-morbidities, suggesting that the previously described link between major depression and the neuropathological processes in Alzheimer's disease may be related to changes in neuronal survival mediated by neurotrophic factors.Funded by the National Institute on Aging (U01 AG016976 and NIA P01-AG05138) and NARSAD.

Antidepressant use in Alzheimer's disease patients: results of the REAL.FR cohort

2009 ◽  
Vol 22 (1) ◽  
pp. 120-128 ◽  
Author(s):  
Christophe Arbus ◽  
Virginie Gardette ◽  
Eric Bui ◽  
Christelle Cantet ◽  
Sandrine Andrieu ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Depressive Symptoms ◽  
Previous History ◽  
Natural Setting ◽  
Antidepressant Prescription ◽  
History Of ◽  
Antidepressant Use ◽  
Clinically Significant ◽  
History Of Depression

ABSTRACTBackground: Psychotropic medication is widely prescribed in clinical practice for the management of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD). However, there have been few pharmaco-epidemiological studies or studies conducted in a natural setting on the real use of antidepressants in AD. The aim of this survey was to assess the prevalence of antidepressant use in AD and to identify the clinical factors associated with antidepressant prescription.Methods: REAL.FR is a four-year, prospective, multi-center study. Baseline data including demographic characteristics, clinical variables and drug intake were obtained. Depressive symptoms were determined using the Neuropsychiatric Inventory (NPI).Results: A total of 686 AD patients were included. Antidepressant treatment was prescribed for 34.8% of patients. Clinically significant depressive symptoms (NPI ≥ 4) were observed in 20.5% of the total population. Although depressed subjects were significantly more likely to be treated with antidepressants than non-depressed subjects (p<0.0001), only 60% of depressed subjects overall were prescribed an antidepressant. In multivariate analysis, clinically significant depressive symptoms were associated with antidepressant prescription although this result was only observed in subjects without a previous history of depression.Conclusions: The available data on antidepressant efficacy in BPSD other than depression (in particular, agitation, aggression and, occasionally, psychotic symptoms) do not influence prescription choices. Depressive symptoms may be taken more seriously in the absence of a previous history of depression, leading to increased antidepressant prescription rates in individuals presenting with depression for the first time.

P1-220: History of depression and risk of hippocampal atrophy and future Alzheimer's disease

2006 ◽  
Vol 2 ◽  
pp. S160-S161
Author(s):  
Mirjam I. Geerlings ◽  
Tom den Heijer ◽  
Peter J. Koudstaal ◽  
Albert Hofman ◽  
Monique M.B. Breteler
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Hippocampal Atrophy ◽  
History Of ◽  
History Of Depression

Markers for depression in Alzheimer's disease

2006 ◽  
Vol 18 (1) ◽  
pp. 25-29 ◽  
Author(s):  
Ruud van Winkel ◽  
Albert F. G. Leentjens ◽  
Frans R. J. Verhey
Keyword(s):  
Risk Factors ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
General Population ◽  
Logistic Model ◽  
Predictive Power ◽  
History Of ◽  
Independent Marker ◽  
History Of Depression ◽  
Disease Specific

Objective:The aim of this study was to evaluate whether risk factors for depression in the general population are also markers for depression in Alzheimer's disease (AD) and to identify additional disease-specific markers for depression in AD.Patients and methods:A logistic model of five risk factors for depression in the general population was constructed using the data of 217 patients with AD, of whom 63 (29%) suffered from major depressive disorder. In a next step, five potential disease-specific markers were individually added to this model to see whether the strength and predictive power of the model would improve.Results:The multivariate model of five risk factors for depression in the general population was not a good model to predict depression in AD. In this multivariate approach, only ‘a history of depression’ was an independent marker for depression. The only disease-specific variable that improved the logistic model was ‘disability due to AD’. An interaction between these two markers became apparent.Conclusions:Of the established risk factors for depression in the general population, only ‘a history of depression’ was found to be an independent marker for depression in AD. ‘Disability due to AD’ was the only disease-related marker for depression in AD, although this marker cannot be considered specific for AD. The importance of controlling for general risk factors for depression in the search for disease-specific markers for depression in AD is stressed.

Association between Premorbid History of Depression and Current Depression in Alzheimer's Disease

1999 ◽  
Vol 12 (2) ◽  
pp. 72-75 ◽  
Author(s):  
Dylan G. Harwood ◽  
Warren W. Barker ◽  
Raymond L. Ownby ◽  
Ranjan Duara
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
History Of ◽  
History Of Depression

Personal history of depression and its appearance in Alzheimer's disease

1995 ◽  
Vol 10 (8) ◽  
pp. 669-678 ◽  
Author(s):  
Brian D. Carpenter ◽  
Milton E. Strauss ◽  
John S. Kennedy
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Personal History ◽  
History Of ◽  
History Of Depression

scholarly journals Association between depression and the risk of Alzheimer’s disease using the Korean National Health Insurance Service-Elderly Cohort

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hyunkyu Kim ◽  
Wonjeong Jeong ◽  
Junhyun Kwon ◽  
Youseok Kim ◽  
Eun-Cheol Park ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Health Insurance ◽  
National Health Insurance ◽  
National Health ◽  
Depression Group ◽  
History Of ◽  
Korean National Health Insurance ◽  
Elderly Cohort ◽  
History Of Depression

AbstractIn this cohort study, we assessed the association between depression and the risk of Alzheimer’s disease from data obtained from the 2002 to 2013 Korean National Health Insurance Service-Elderly Cohort Database, which accounts for 10% of the South Korean population aged > 60 years. A total 518,466 patients were included in the analysis and followed up, unless they were excluded due to death or migration. Patients who sought treatment for depression or dementia within 1 year of the washout period and who were diagnosed with dementia within the 1-year period of the diagnosis of depression were excluded from the study. The risk of dementia was analysed using Cox proportional hazards models. Patients with a history of depression during the follow-up period were at a higher risk of Alzheimer’s disease than those without a history of depression (HR 3.35, CI 3.27–3.42). The severe-depression group exhibited the highest risk of Alzheimer’s disease (HR 4.41, CI 4.04–4.81), while the mild-depression group exhibited a relatively lower risk of Alzheimer’s disease (HR 3.31, CI 3.16–3.47). The risk of Alzheimer’s disease was associated with depression history and an increased severity of depression increased the risk of Alzheimer’s disease.

Premorbid History of Major Depression and the Depressive Syndrome of Alzheimer's Disease

1996 ◽  
Vol 4 (1) ◽  
pp. 85-90
Author(s):  
George S. Zubenko ◽  
Ph.D., A. Hind Rifai ◽  
Benoit H. Mulsant ◽  
Robert A. Sweet ◽  
Rona E. Pasternak
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Major Depression ◽  
Depressive Syndrome ◽  
History Of

Beneficial Influence of Agomelatine Treatment on Behavioral Impairments in AΒ-Induced Rat Model of Alzheimer’s Disease

2020 ◽  
Vol 13 (2) ◽  
pp. 116-121
Author(s):  
Kalina St. Ilieva ◽  
Jana D. Tchekalarova ◽  
Milena A. Atanasova ◽  
Lidiya P. Petrova
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Memory Errors ◽  
Model Of Alzheimer’S Disease ◽  
Promising Therapeutic Approach ◽  
Increased Risk ◽  
History Of ◽  
Intraperitoneal Treatment ◽  
Behavioral Impairments ◽  
History Of Depression

Summary An increased risk of developing Alzheimer’s disease (AD) exists in patients with a history of depression. In the present study, we demonstrated that chronic agomelatine intraperitoneal treatment, at a dose of 40 mg/ kg for 21 days, starting one month after inducing AD by intracerebroventricular injection of amyloid-beta (Aβ) corrected anhedonia, decreased anxiety, and showed a potential to mitigate working memory errors during the last session in a radial arm maze. Altogether, our findings suggest that chronic agomelatine administration treatment could alleviate the burden of AD and may be considered a promising therapeutic approach to some adverse symptoms caused by the disease.

Sign in / Sign up

Export Citation Format

Share Document